Littlefield MJ - Search Results

1

Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux.

Voloshyna I, Teboul I, Littlefield MJ, Siegart NM, Turi GK, Fazzari MJ, Carsons SE, DeLeon J, Reiss AB. Voloshyna I, et al. Among authors: littlefield mj. Exp Biol Med (Maywood). 2016 Aug;241(14):1611-9. doi: 10.1177/1535370216647181. Epub 2016 Apr 27. Exp Biol Med (Maywood). 2016. PMID: 27190277 Free PMC article.

2

Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine.

Voloshyna I, Hai O, Littlefield MJ, Carsons S, Reiss AB. Voloshyna I, et al. Among authors: littlefield mj. Eur J Pharmacol. 2013 Jan 5;698(1-3):299-309. doi: 10.1016/j.ejphar.2012.08.024. Epub 2012 Oct 4. Eur J Pharmacol. 2013. PMID: 23041272

3

Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages.

Voloshyna I, Modayil S, Littlefield MJ, Belilos E, Belostocki K, Bonetti L, Rosenblum G, Carsons SE, Reiss AB. Voloshyna I, et al. Among authors: littlefield mj. Exp Biol Med (Maywood). 2013 Oct;238(10):1192-7. doi: 10.1177/1535370213503262. Epub 2013 Sep 2. Exp Biol Med (Maywood). 2013. PMID: 24000379 Free PMC article.

4

Infliximab reverses suppression of cholesterol efflux proteins by TNF-α: a possible mechanism for modulation of atherogenesis.

Voloshyna I, Seshadri S, Anwar K, Littlefield MJ, Belilos E, Carsons SE, Reiss AB. Voloshyna I, et al. Among authors: littlefield mj. Biomed Res Int. 2014;2014:312647. doi: 10.1155/2014/312647. Epub 2014 Jan 23. Biomed Res Int. 2014. PMID: 24587984 Free PMC article.

5

Plasma IL-33 in atopic patients correlates with pro-inflammatory cytokines and changes cholesterol transport protein expression: a surprising neutral overall impact on atherogenicity.

Voloshyna I, Mucci T, Sher J, Fonacier LS, Littlefield MJ, Carsons S, Reiss AB. Voloshyna I, et al. Among authors: littlefield mj. Clin Exp Allergy. 2015 Oct;45(10):1554-65. doi: 10.1111/cea.12516. Clin Exp Allergy. 2015. PMID: 25703059 Clinical Trial.

6

COX-2 inhibition and inhibition of cytosolic phospholipase A2 increase CD36 expression and foam cell formation in THP-1 cells.

Anwar K, Voloshyna I, Littlefield MJ, Carsons SE, Wirkowski PA, Jaber NL, Sohn A, Eapen S, Reiss AB. Anwar K, et al. Among authors: littlefield mj. Lipids. 2011 Feb;46(2):131-42. doi: 10.1007/s11745-010-3502-4. Epub 2010 Dec 22. Lipids. 2011. PMID: 21181286

7

Adenosine A(2A) receptor activation supports an atheroprotective cholesterol balance in human macrophages and endothelial cells.

Voloshyna I, Carsons S, Littlefield MJ, Rieger JM, Figler R, Reiss AB. Voloshyna I, et al. Among authors: littlefield mj. Biochim Biophys Acta. 2013 Feb;1831(2):407-16. doi: 10.1016/j.bbalip.2012.11.005. Epub 2012 Nov 17. Biochim Biophys Acta. 2013. PMID: 23168167

8

Atherosclerosis and interferon-γ: new insights and therapeutic targets.

Voloshyna I, Littlefield MJ, Reiss AB. Voloshyna I, et al. Among authors: littlefield mj. Trends Cardiovasc Med. 2014 Jan;24(1):45-51. doi: 10.1016/j.tcm.2013.06.003. Epub 2013 Aug 2. Trends Cardiovasc Med. 2014. PMID: 23916809 Free PMC article. Review.

9

COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.

Voloshyna I, Kasselman LJ, Carsons SE, Littlefield MJ, Gomolin IH, De Leon J, Reiss AB. Voloshyna I, et al. Among authors: littlefield mj. J Investig Med. 2017 Mar;65(3):694-704. doi: 10.1136/jim-2016-000259. Epub 2016 Dec 9. J Investig Med. 2017. PMID: 27940550

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters